("Diaceutics" or "the Group")
Capital Markets Day
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, hosted a virtual Capital Markets Day ("CMD") for investors and equity analysts on Wednesday 16th June 2021.
The event was hosted by Group CEO, Peter Keeling, and included a series of presentations, a demonstration of the DXRX SaaS platform, and views from an industry expert panel including:
- Pharmaceutical Partner: a senior executive within one of the world’s top five pharmaceutical companies
- Laboratory Partner: Professor Giancarlo Pruneri, Head of Pathology Fondazione IRCCS Istituto Nazionale Tumori, Milan
- Key Opinion Leader: Dr Avi Kulkarni, SVP and R&D leader at Nasdaq listed technology firm Cognizant
In addition, a strategic update was heard from the Company, along with a live Q&A.
If you are interested in the contents or have any questions relating to the Diaceutics Capital Markets Day please contact [email protected]
Peter Keeling, Chief Executive Officer
Philip White, Chief Financial Officer
via Alma PR
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)
+44 (0)20 7710 7600
Tel: +44 (0)20 3405 0205
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world’s leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX – The Diagnostic Network®.
DXRX is the world’s first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.